SCHEMBL3822964

SCHEMBL3822964

CN1C(=O)c2ccc(Oc3cccc4c3C(=O)N(C)C4=O)cc2C1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
KMT2A Q03164 9/20 0.47
MEN1 O00255 6/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 2/20 0.45
LMNA P02545 2/20 0.44
APP P05067 1/20 0.43
USP2 O75604 2/20 0.42
CASP1 P29466 1/20 0.42
BRCA1 P38398 1/20 0.42
CASP7 P55210 1/20 0.42
PRMT1 Q99873 1/20 0.42
BRD4 O60885 1/20 0.42
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
CASP3 P42574 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11077941 0.89 SMN1; SMN2 (0.51) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL21348853 0.87 KMT2A (0.57) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL3819746 0.84 MEN1 (0.51) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL21348856 0.83 SMN1; SMN2 (0.50) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL261589 0.82 TDP1 (0.71) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL260975 0.82 SMN1; SMN2 (0.57) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL27553341 0.81 KMT2A (0.49) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL262253 0.81 ALDH1A1 (0.57) TDP1KMT2AMEN1ALDH1A1MAPT
SCHEMBL11077691 0.80 ALDH1A1 (0.44) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1
SCHEMBL19927865 0.80 ALDH1A1 (0.44) SMN1; SMN2TDP1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097375-B1 METHOD FOR PURIFYING BISIMIDES SABIC INNOVATIVE PLASTICS IP (NL) 2013-04-24 EP claimed
EP-2097375-A1 METHOD FOR PURIFYING BISIMIDES Sabic Innovative Plastics IP B.V. (NL) 2009-09-09 EP claimed
US-7408070-B2 Method for purifying bisimides SABIC INNOVATIVE PLASTICS IP B.V. (US) 2008-08-05 US claimed
WO-2008063208-A1 METHOD FOR PURIFYING BISIMIDES SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2008-05-29 WO claimed
US-20070073063-A1 Method for purifying bisimides GENERAL ELECTRIC COMPANY (US) 2007-03-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070073063-A1 Method for purifying bisimides FHIT, PBRM1, TNS4 SMN1; SMN2 1842/4885TDP1 2431/4885KMT2A 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.